Qpex Biopharma

Overview: Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a global pharmaceutical company with a long history of bringing innovative medicines to patients. Building on its leadership in infectious disease, Shionogi Inc. is establishing a best-in-class rare disease franchise. The company’s growing rare disease team is helping shape the future of RADICAVA® (edaravone) for the amyotrophic lateral sclerosis (ALS) community. In the United States, RADICAVA® has an established legacy, with the injectable formulation launched in 2017 and the oral suspension introduced in 2022. Building on that strong foundation, Shionogi is focused on advancing RADICAVA with a commitment to scientific excellence, patient impact and long-term innovation in rare disease. The Neurology Account Specialist (NAS) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing...